SONIDA SENIOR LIVING, INC. acquires CHP for USD 404,400,000 (2026)

Deal facts

Buyer: SONIDA SENIOR LIVING, INC.
Target: CHP
Deal value: USD 404,400,000
Announced: 11 March 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, shares

Sources

What we know

SONIDA SENIOR LIVING, INC. has agreed to acquire CHP in a strategic acquisition within the US healthcare sector. The transaction, announced on 11 March 2026, involves a headline offer value of 404.4 million USD. Consideration for the deal comprises a combination of cash and shares, reflecting the financial structure agreed upon by both parties. The target operates as a distinct entity within the United States, and the buyer is also based in the US, facilitating a domestic consolidation of assets.

The transaction was reported as completed on 10 March 2026, indicating that the deal closed shortly after the public announcement. This sequence suggests a rapid execution of the agreement between the management teams and regulatory bodies. The deal represents a significant capital deployment for the buyer in the senior living segment. The transaction is subject to regulatory approval.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

10 Mar 2026CompletedClosed
SONIDA SENIOR LIVING, INC. completes acquisition of CHP
INTRODUCTORY NOTE As previously announced, on November 4, 2025, Sonida Senior Living, Inc., a Delaware corporation (the “ Company ” or “ SNDA ”), SSL Sparti LLC, a Delaware limited liability company and a wholly owned subsidiary of SNDA (“ Holdco ”), SSL Sparti Property Holdings Inc. (f/k/a Sparti Merger Sub, Inc.), a Maryland corporation and wholly owned subsidiary of Holdco (“ SNDA Merger Sub ”)
Source

OpinionExit Mode editorial

We see a clear signal in the announced completion of Sonida Senior Living, Inc.'s acquisition of CHP for 404.4 million USD. This strategic move within the US healthcare sector underscores a continued consolidation trend where scale is the primary driver. The deal structure, mixing cash and shares, is a classic mechanism used to balance immediate liquidity for sellers against the buyer's desire to preserve capital and align long-term interests. For the SME founder watching from the other side of the Atlantic, this transaction highlights how cross-border capital flows remain active even as domestic markets tighten. The mix of consideration types often signals that the buyer values the target's future growth potential enough to share that upside through equity, while the cash component provides a necessary floor for the selling shareholders.

The regulatory context here is straightforward given the US domestic nature of the deal, yet it still demands scrutiny. While no specific antitrust thresholds are breached in the public record, any healthcare consolidation of this magnitude invites scrutiny from the Federal Trade Commission regarding market concentration. The fact that this deal is already marked as completed suggests that all necessary regulatory clearances were obtained without material impediment. This is a critical lesson for founders in regulated sectors: the path to completion is often paved with early engagement on competition and change-of-control covenants. Ignoring these mechanics until the signing stage is a recipe for delay or termination. The speed of this transaction implies that due diligence was rigorous and that the parties anticipated the regulatory hurdles before they became obstacles.

Our view is that the structure of this deal offers a blueprint for founders seeking an exit in capital-intensive sectors. The blend of cash and shares allows the buyer to manage their balance sheet while retaining key talent from the target through equity incentives. This is not merely a financial transaction but an operational integration strategy. The SME founder must understand that accepting shares in the buyer means taking on the risk of the acquirer's future performance. You are no longer just selling a business; you are buying into the buyer's future. This shift in risk profile requires a clear understanding of the buyer's market position and financial health before you sign the papers.

Your immediate action this week is to request a full breakdown of the consideration mix in your current term sheet discussions. Do not accept a headline value without knowing the exact ratio of cash to shares and the vesting schedule attached to any equity component. If the deal involves shares, demand a one-page summary of the buyer's debt covenants and recent trading volatility to assess the real risk of that portion of your exit.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from SONIDA SENIOR LIVING, INC.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

13 October 2026CompletedHealthcare

Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.

Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…

Buyer: Alaunos Therapeutics, Inc.
Target: Velaris Therapeutics, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

11 October 2026Firm intentionHealthcare

STERIS Corporation to acquire Xodus Medical, Inc.

STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…

Buyer: STERIS Corporation
Target: Xodus Medical, Inc.
Deal value: USD 2,100,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

9 October 2026CompletedHealthcare

Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC

Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…

Buyer: Hepion Pharmaceuticals, Inc.
Target: Gravitas Life Sciences, LLC
Deal value: USD 4,250,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history